Using B7-H3 imaging to guide osteosarcoma surgery
Part of Cancer clinical trials.
This trial tests a special dye that targets B7-H3, a protein found on osteosarcoma cells. Before your surgery, the dye is injected and helps surgeons see tumor edges more clearly, so they can remove all of the cancer while saving healthy tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have osteosarcoma in an arm or leg that has been confirmed by a biopsy.
- You have not yet had surgery to remove the tumor.
- You are between 18 and 60 years old.
- You have not received any chemotherapy or other treatment for your osteosarcoma.
- An MRI or CT scan shows the tumor can be measured.
- Your bone marrow, liver, and kidney function are adequate based on blood tests.
- You are not pregnant or breastfeeding, and have not had another cancer in the last 5 years.
- You are not allergic to any part of the imaging agent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new PET imaging tracer that may help see osteosarcoma tumors more clearly. It is for people whose osteosarcoma has not improved or has returned after standard treatment.
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
This trial uses a lab-grown mini tumor (organoid) from your biopsy to test which drugs might work best for your osteosarcoma. It aims to personalize your treatment based on how your specific cancer cells respond.
This trial tests a combination of immunotherapy and targeted radiation before surgery for osteosarcoma that has spread to the lungs. It aims to see if this approach can help shrink or control the lung tumors and make surgery more effective.
This trial tests a single, high-dose internal radiation treatment (brachytherapy) for large osteosarcoma tumors that can't be removed by surgery and haven't responded to other treatments. It may offer a new option for shrinking these difficult-to-treat masses.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.